The increasingly cash-rich Novo Nordisk Foundation has teamed up with Wellcome and the Bill & Melinda Gates Foundation to support what the partners call "critical scientific R&D for global health" to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).
Novo Nordisk Foundation Strengthens Ties With Gates
The two heavyweights have joined forces with fellow major charitable foundation Wellcome and committed $300m to "accelerate global health equity and impact."
More from Financing
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
More from Business
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.